Option chain shows key data for Lifeist Wellness Inc's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Lifeist Wellness Inc.

Lifeist Wellness Inc (OTC:LFSWD) Stock, Option Chain

Cannabis

News

Market-Moving Exclusives

LFSWD

Discover how Anson Funds settled with the SEC for $2.25M over an undisclosed collaboration with short seller impacting cannabis stocks

Hedge Fund Settles At $2.25M With SEC For Exposed Short Seller Deal, 2 Cannabis Stocks Affected

Lifeist Wellness Inc

Amcon Distributing (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/DIT#AMEX">DIT</a>) reported quarterly earnings of $0.57 per share. This is a 67.98 percent decrease over earnings of $1.78 per share from the same period last year. The company reported $711.27 million in sales this quarter. This is a 10.28 percent increase over sales of $644.96 million the same period last year.

Earnings

Reported Monday, Amcon Distributing Q1 EPS $0.57 Down From $1.78 YoY, Sales $711.27M Up From $644.96M YoY

<ul>
<li>Significant portfolio expansion to include combat-proven autonomous airborne platforms in support of critical forward-looking national security mission needs</li>
<li>Expected to be immediately accretive to Revenue, Adjusted EBITDA and Free Cash Flow</li>
<li>Post-transaction, Redwire expects to have a strong balance sheet</li>
</ul>

Reported Sunday, Redwire To Acquire Edge Autonomy In $925M Deal, Transforming Into A Multi-Domain Space And Defense Leader

Collaboration will bring bespoke content and never-before-seen show integrations

Reported Sunday, BetMGM Secures Online Casino Rights For Fremantle's "Family Feud" And "The Price Is Right"

Programming Already Restored for Two Million Viewers, Including NFL Playoff Games and Local News

ATUS

NXST

Reported Saturday, Nexstar And Optimum Reach Agreement To Restore Programming For Two Million Customers

<a href="https://www.globenewswire.com/Tracker?data=ZJKetO8zE3erzqRGF_P7-sCgwYhySBueJMgNqynfM3aNltyVHIqgYbS_u8Uz3Nv7SKdETdCLI16Ppo7Wvc4v8A==">NANOBIOTIX</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating potential first-in-class radioenhancer JNJ-1900 (NBTXR3) for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab (<a href="https://www.globenewswire.com/Tracker?data=9AF1jPR-HWZ8jVuLKKF7MX10tUChZ_X2NGuXvAVUyFwhfw23CgjxX9aY63wN0Kdaec4QfEQsIuazNYZjxTvGX2JHp8IO-l0T8OXn7FrEKgkLxinTtGOoP8RlFCRY0HK-ieJqCKDibtD2Daq_RvrOBA==">NCT06667908</a>). CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson &amp; Johnson Company, under a global license agreement.

NBTX

Nanobiotix Begins Phase 2 Trial for Innovative Cancer Treatment in Stage 3 Lung Cancer

ARBK

Argo Blockchain CEO Thomas Chippas To Exit; CFO Jim MacCallum Appointed As Interim Successor

The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/SCHW/earnings">opening bell, on Tuesday, Jan. 21, 2025.</a>
Analysts expect the Westlake, Texas-based company to report quarterly earnings at 91 cents per share, up from 68 cents per share in the year-ago period. Charles Schwab projects quarterly revenue of $5.2 billion, compared to $4.46 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 13, Charles Schwab said it expects FY24 net revenue to grow by 3.0%-3.5% versus the prior year.
Charles Schwab shares gained 1.2% to close at $76.41 on Friday&nbsp;&nbsp;&nbsp; .
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/SCHW/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Wells Fargo analyst Michael Brown maintained an Equal-Weight rating and cut the price target from $90 to $89 on Jan. 14, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Citigroup analyst Christopher Allen maintained a Neutral rating and cut the price target from $85 to $80 on Jan. 10, 2025. This analyst has an accuracy rate of 77%.</li>
<li>JP Morgan analyst Kenneth Worthington maintained an Overweight rating and raised the price target from $87 to $93 on Jan. 7, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Piper Sandler analyst Patrick Moley maintained a Neutral rating and raised the price target from $65 to $70 on Jan. 7, 2025. This analyst has an accuracy rate of 81%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintained an Outperform rating and raised the price target from $81 to $93 on Dec. 20, 2024. This analyst has an accuracy rate of 65%.</li>
</ul>
Considering buying SCHW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-1024x576.png" alt="" class="wp-image-741030" style="width:574px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43054647/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-with-over-9-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks With Over 9% Dividend Yields</a></li>
</ul>

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

SCHW

Charles Schwab Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

GOEV

Reported Friday, Canoo Announces Chapter 7 Bankruptcy Filing, Ending Operations Effective Immediately

SPPL

Reported Friday, SIMPPLE Receives Nasdaq Notifications For Minimum Equity And Annual Meeting Deficiencies

Macro Economic Events

Econ #s

Economics

U.K. Unemployment Rate For November 4.4% Vs. 4.3% Est.; 4.3% Prior

U.K. Employment Change 3M/3M (MoM) For November 35K Vs. 35K Est.; 173K Prior

U.K. Claimant Count Change For December 0.7K Vs. 10.3K Est.; -25.1K (Revised) Prior

U.K. Average Earnings Index +Bonus For November 5.6% Vs. 5.6% Est.; 5.2% Prior

<ul>
<li>Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function</li>
<li>The transdermal GFR (tGFR) methodology has been designed to be effective across the adult population without input of age, weight, sex, gender, race, or ethnicity</li>
<li>More than 800 million people have Chronic Kidney Disease (CKD), one of the world's leading causes of mortality worldwide, with associated deaths increasing over the past two decades1</li>
</ul>

VATE

Reported Friday, INNOVATE Announces FDA Approval Of MediBeacon's TGFR System For Accurate Kidney Function Testing

MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares dropped 2.35% in overnight trading on Robinhood Markets on Tuesday, falling to $386.80 as cryptocurrency markets reacted to President Donald Trump&#8216;s inauguration speech that notably <a href="https://www.benzinga.com/25/01/43086698/crypto-market-plunges-after-trumps-inaugural-speech-fails-to-mention-digital-assets">omitted any mention of digital assets</a>.
What Happened: The enterprise software company, which holds over $45 billion in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), had seen its stock surge 8.04% to $396.50 on Friday amid optimism about Trump&#8217;s anticipated crypto-friendly policies. 
The company&#8217;s executive chairman Michael Saylor attended a &#8220;Crypto Ball&#8221; last Friday where he met with Trump&#8217;s incoming cabinet members, fueling speculation about <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43078515/michael-saylor-meets-trumps-cabinet-at-crypto-ball-what-does-the-bitcoin-bulls-cryptic-post-indicate">favorable cryptocurrency regulations</a>.
However, Trump&#8217;s inaugural address focused instead on traditional assets, declaring the start of a &#8220;Golden Age of America&#8221; &#8211; a reference that prompted Bitcoin critic Peter Schiff to highlight the president&#8217;s apparent preference for gold over cryptocurrency. 
See Also: <a href="https://www.benzinga.com/25/01/43088034/bitcoin-ethereum-dogecoin-retrace-from-pre-inauguration-highs-as-trumps-address-disappoints-analyst-highlights-possibility-of-btc-consolidation-in-101k-106k-range">Bitcoin, Ethereum, Dogecoin Retrace From Pre-Inauguration Highs As Trump Skips Crypto Mention: Analyst Highlights BTC Consolidation In $101K-$106K Range</a>
Why It Matters: The speech&#8217;s omission of digital assets triggered a broader <a href="https://www.benzinga.com/25/01/43088563/bitcoin-vs-gold-peter-schiff-decodes-trumps-golden-age-reference-in-inaugural-speech">crypto market decline</a>, with Bitcoin falling from $106,000 to $101,775.
The selloff comes as Trump named Mark Uyeda as acting U.S. Securities and Exchange Commission chair, replacing Gary Gensler. 
The firm has been purchasing Bitcoin for ten consecutive weeks, according to its public disclosures.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43088840/donald-and-melania-trump-memecoins-crash-after-presidential-inaugurationfirst-couples-crypto-wealth-plunges-36">Donald And Melania Trump Memecoins Crash, Erode Billions In Investors&#8217; Wealth</a></li>
</ul>
Image Via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

$BTC

MSTR

MicroStrategy Drop 2.35% On Overnight Trading After Trump's Inauguration Speech Sidelines Cryptocurrency, Bitcoin Retreats Below $102K

Uniti intends to use the net proceeds of the offering to, among other things, repay and terminate its existing ABS bridge facility and for general corporate purposes, which may include success-based capital investments and/or repayment of outstanding debt.

UNIT

Reported Friday, Uniti Group Prices $589M Fiber Securitization Notes Secured By Florida And Gulf Coast Assets With 2030 Repayment Target

EZGO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) reported quarterly losses of $(2.80) per share. This is a 53.33 percent increase over losses of $(6.00) per share from the same period last year. The company reported $21.10 million in sales this quarter. This is a 32.53 percent increase over sales of $15.92 million the same period last year

EZGO

Reported Friday, EZGO Technologies FY EPS $(2.80) Up From $(6.00) YoY, Sales $21.10M Up From $15.92M YoY

<ul>
<li>First approval in the U.S. for Daiichi Sankyo and AstraZeneca's DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death versus chemotherapy</li>
<li>Second DXd antibody drug conjugate approved in U.S. based on Daiichi Sankyo's DXd technology</li>
</ul>

DSNKY

Reported Friday, FDA Approves Daiichi Sankyo And AstraZeneca's DATROWAY AS A New Treatment Option For HR Positive, HER2 Negative Breast Cancer In The U.S.

Billionaire investor and television personality&nbsp;Mark Cuban&nbsp;threw a subtle dig at President Donald Trump&#8217;s newly launched meme coin on Monday, saying that he too can consider launching a similar project but with a major twist.
What Happened: In a series of tweets, Cuban proposed issuing a meme coin,<a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43078040/trump-coin-tanks-36-even-as-melania-trump-launches-her-own-token-top-analyst-says-his-short-is-going-very-very-well"> similar</a> to the Official Trump (TRUMP) token, with a 20% supply open for public trading and following the same unlock schedule. 
The difference? All&nbsp;revenue from the sale of&nbsp;these coins would go directly to the U.S. Treasury. For transparency, Cuban proposed making the details of wallet addresses public.
&#8220;If you want to gamble,&nbsp;gamble. But at least use&nbsp;it to make a dent&nbsp;in the U.S. debt,&#8221; the "Shark" said.
U.S. debt has <a href="https://www.benzinga.com/markets/25/01/43075983/us-dollar-treasury-etfs-oil-prices-chinas-economy-and-ray-dalios-us-debt-warning-this-week-in-economics">ballooned past $36 trillion</a>, with interest payments exceeding $892 billion in fiscal year 2024. The gravity of the issue could be gauged by the fact that the U.S. accounts for 34.6% of global debt.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If meme coins are the way, maybe I'll issue one. With a twist. Same terms as <a href="https://twitter.com/search?q=%24TRUMP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TRUMP</a> . 20% float. Same release schedule. One difference. All the revenue from the sale of the coins go to the US Treasury. The wallet address will be published so everyone can track it. If…
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1881445569727758392?ref_src=twsrc%5Etfw">January 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The idea was countered by a widely followed X user going by the pseudonym artchick.eth, who argued that issued by celebrities will not benefit holders in the long run.
Cuban agreed with these assertions, stating that only a few meme coin projects like Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) have been successful, thanks to community engagement.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We agree. It's why Doge, Shibu Inu and only a few others have worked. It's about the community long term. I'm not saying buyers won't get rekt. I said it was gambling. It's a game of musical chairs. No promises. No pumps by me. Just complete transparency
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1881449813042246128?ref_src=twsrc%5Etfw">January 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/25/01/43087038/trump-names-uyeda-acting-sec-chair-as-crypto-regulations-get-set-for-a-makeover">Trump Names Uyeda Acting SEC Chair, Regulators Get Ready For Crypto Makeover</a>
Why It Matters: Cuban&#8217;s statements follow the hysteria sparked by Trump&#8217;s memecoin project, which soared to billions of dollars in market price over the weekend, <a href="https://www.benzinga.com/25/01/43088840/donald-and-melania-trump-memecoins-crash-after-presidential-inaugurationfirst-couples-crypto-wealth-plunges-36">only to plummet </a>on the day of the presidential inauguration.
The Trump memecoin was followed by an official memecoin from First Lady Melania Trump, which similarly crashed after the initial frenzy.
Cuban has previously stated that <a href="https://www.benzinga.com/general/entertainment/24/12/42545829/mark-cuban-expresses-sympathy-for-hawk-tuah-girl-amid-meme-coin-controversy-wasnt-something-she-fully-understood">he is&nbsp;not a fan of memecoins</a>, calling them a "game of musical chairs with&nbsp;money."
Price Action: At the time of writing, TRUMP was exchanging hands at $34.50, crashing 42.43% in the last 24 hours, <a href="https://coinmarketcap.com/currencies/official-trump/">according </a>to CoinMarketCap. MELANIA token tanked 62.88% in the last 24 hours.
Image via Flickr
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43086309/trumps-doge-committee-faces-lawsuit-over-alleged-federal-advisory-violations-and-lack-of-transparency">Trump&#8217;s DOGE Committee Faces Lawsuits Over Alleged Federal Advisory Violations, Lack Of Transparency</a></li>
</ul>

Politics

$DOGE

$SHIB

Mark Cuban Proposes TRUMP-Like Crypto To Lessen US Debt — 'Shark' Counts Dogecoin, Shiba Inu Among  Successful Memecoin Projects

WISeKey Establishes Charity Partnerships to Provide Digital Identities and Financial Inclusion to Over One Billion People

WKEY

WISeKey Joins Forces with Global Organizations To Provide Digital Identities For The Unbanked

Lifeist Wellness (TSE:LFST) has released an update. Lifeist Wellness Inc. has streamlined its business focus by divesting its non-core subsidiary, ...

Lifeist Wellness Refocuses with Strategic Divestiture

Lifeist Wellness (TSE:LFST) has released an update. Lifeist Wellness's subsidiary Mikra has completed the design of their new brain health suppleme...

Comments

Lifeist Wellness Inc

Lifeist Wellness Inc (LFSWD) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga